Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia drug
Biotech
Boehringer's schizophrenia drug fails trio of phase 3 trials
Boehringer’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials.
Gabrielle Masson
Jan 16, 2025 11:58am
LB Pharma's twist on old Sanofi drug passes schizophrenia test
Jan 8, 2025 7:00am
Neurocrine's KarXT rival hits in phase 2—but only at low dose
Aug 28, 2024 7:53am
Karuna's schizophrenia drug clears blood pressure test
Nov 17, 2023 8:52am
Newron's schizophrenia data boost chances of historic approval
Feb 16, 2023 8:30am
Karuna hits goal in schizophrenia phase 3, teeing up 2023 filing
Aug 8, 2022 9:48am
